Phoenicia Scientists were awarded a new US patent (8,759,378, Issued June 24, 2014: “Methods for Treating Blood Disorders”), covering newly-discovered small molecules which regulate fetal globin production for the treatment of β-thalassemia and sickle cell disease
Phoenicia scientists were recently awarded a Phase 2 Small Business Grant from the NIH NHLBI (“Development of a Clinical Hemoglobin Modulator” R42 HL-110727-02) to support clinical development of PB-04, the lead drug candidate for the treatment of β-thalassemia and sickle cell disease
Phoenicia’s lead drug candidate for the treatment of β-thalassemia and sickle cell disease (PB-04), was recently selected as a project within the Therapeutics for Rare and Neglected Diseases program at the NIH’s National Center for Advancing Translational Sciences. Through our collaboration with TRND researchers, we gain access to preclinical drug development expertise. The goal of the TRND program is to work with collaborators to advance potential treatments to human clinical trials.
A virus-targeted therapy for
Epstein Barr virus associated lymphomas
Phoenicia is working to bring an innovative therapeutic approach for deadly EBV-associated lymphomas into clinical trials with a new generation and oral virus-targeted therapeutic.
Phoenicia Founder Douglas V. Faller developed a method to activate silent genes within the dormant EBV virus, which resides in lymphoma cells.
The EBV virus, whether a “passenger” or the cancer-causing agent, can then serve as a target for therapeutics. Activating the viral TK gene causes activation of a common antiviral pro-drug, selectiving killing the lymphoma cells containing the virus. Continue reading
NIH grant to convert a potent IV
therapy for refractory wounds into
a topical formulation
Phoenicia has received a new small business grant from the National Institutes of Health for studies to convert an intravenous therapy which healed refractory, disabling leg ulcers in hemolytic anemias, sickle cell disease and β-thalassemia, into a topical preparation which can be used readily by patients world-wide. Continue reading
The mission of Phoenicia Biosciences is to advance the development and translation of therapies for serious medical conditions for which current treatments are inadequate or lacking, particularly diseases affecting global populations.